THBD and septic shock: In a post hoc analysis of the ‘neutral’ Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial (SCARLET), the authors reported lower mortality in patients with septic shock associated coagulopathy and elevated coagulation markers (prothrombin fragment 1.2, thrombin–antithrombin complex, d-dimer) treated with thrombomodulin, suggesting this coagulation pattern could be used to select patients most likely to respond [41].